Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in children and adults

Next Previous
Trial Profile

A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in children and adults

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TCR alphabeta-CD19-depleted peripheral blood stem cell therapy (Primary)
  • Indications Acute myeloid leukaemia; Aplastic anaemia; Haematological malignancies; Hodgkin's disease; Leukaemia; Lysosomal storage diseases; Metabolic disorders; Multiple myeloma; Myelodysplastic syndromes; Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma; Sickle cell anaemia; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms TCRalpha/beta-Haplo2010
  • Sponsors Miltenyi Biotec GmbH

Most Recent Events

  • 04 Dec 2018 Status changed to completed as per results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
  • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
  • 12 Dec 2017 Results (n=30) assessing one year safety and efficacy follow-up, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top